Roger Graham appointed president of Mylan Specialty
pharmafile | June 25, 2013 | Appointment | Manufacturing and Production, Research and Development, Sales and Marketing |Â Â Mylan, graham, specialtyÂ
Mylan has hired previous J&J vice president Roger Graham to be president of its specialty business.
Graham will report to Tony Mauro, president of Mylan North America.
Chief executive Heather Bresch said: “Roger’s deep brand pharmaceutical industry experience, entrepreneurial mind-set and goal-oriented leadership make him the ideal candidate to lead Mylan Specialty as we continue to expand this important business.
“We remain very excited about the growth prospects of the Specialty business and are confident that Roger will bring immediate value to our entire North American organisation and help accelerate achievement of our ambitions for Mylan Specialty.”
Graham joins Mylan from Advandx, a private developer of in-vitro diagnostic tests in the infectious disease space. He was the company’s chief commercial officer and developed its growth strategy for the US and European markets.
Prior to that, Graham spent nearly a decade in executive-level marketing and sales positions at three firms: Auxilium Pharmaceuticals, Adolor Corporation and Yamanouchi Pharma America, where he established, rebuilt and/or expanded US commercial operations.
Earlier, Graham worked at Ortho McNeil, a division of Johnson & Johnson, where he was vice president of the company’s $2 billion anti-infective, analgesia and urology franchise, and its 2,300 primary care and hospital sales and marketing associates.
Graham previously served as director of Marketing for Roche’s CNS, pain and dermatology franchises. He began his career with Schering-Plough and, over nearly a decade, took on positions of increasing responsibility in the company’s allergy, respiratory and oncology sales and marketing organisations.
Related Content
Pfizer to pay $345 million in EpiPen lawsuit
Pfizer has reached a $345 million settlement over consumer claims they overpaid for EpiPens as …
Mylan reaches agreement with Aspen for their European thrombosis business
Mylan has announced an agreement to acquire the intellectual property and commercialisation rights to Aspen’s …
Mylan secures first FDA approval for generic version of Biogen’s Tecfidera following patent dispute
The FDA has approved its first generic of Biogen’s multiple sclerosis (MS) treatment Tecfidera, awarding …
